Phase 1 Parkinson Clinical Trials
59 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 59 trials
Recruiting
Phase 1Phase 2
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
Parkinson Disease
University of Alabama at Birmingham205 enrolled1 locationNCT03457493
Recruiting
Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
DementiaParkinson's Disease
National Institute of Mental Health (NIMH)184 enrolled1 locationNCT04396873
Recruiting
Phase 1
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
PARKINSON DISEASE (Disorder)Advanced Parkinson's Disease
Serina Therapeutics40 enrolled6 locationsNCT07422675
Recruiting
Phase 1Phase 2
rTMS to Improve Cognition in Parkinson's
Mild Cognitive ImpairmentParkinson's Disease
VA Office of Research and Development56 enrolled2 locationsNCT03836950
Recruiting
Phase 1
Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
Parkinson DiseaseParkinson's Disease
Innopeutics Corporation6 enrolled1 locationNCT07371338
Recruiting
Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Parkinson Disease
Eli Lilly and Company127 enrolled14 locationsNCT06809400
Recruiting
Phase 1
A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease
Parkinson Disease
University of Michigan5 enrolled1 locationNCT07543861
Recruiting
Phase 1
First-in-Human Single and Multiple Dose of HL-400
Parkinson Disease
Highlightll Pharmaceutical (USA) LLC86 enrolled1 locationNCT06997484
Recruiting
Phase 1
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
iRegene Therapeutics Co., Ltd.9 enrolled1 locationNCT07289477
Recruiting
Phase 1
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
Parkinsons Disease
Regeneron Pharmaceuticals46 enrolled2 locationsNCT07216066
Recruiting
Phase 1
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
Parkinsons Disease (PD)
Pravat Mandal12 enrolled1 locationNCT07064005
Recruiting
Phase 1
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
Multiple System AtrophyParkinsons Disease
Craig van Horne, MD, PhD7 enrolled1 locationNCT06683365
Recruiting
Phase 1
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
Parkinson Disease
Jeffrey S. Schweitzer, MD, PhD8 enrolled1 locationNCT06687837
Recruiting
Phase 1
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
Healthy Volunteers (HV)Parkinson's Disease (PD)
Vertero Therapeutics84 enrolled1 locationNCT07310264
Recruiting
Phase 1
[18F]F-DOPA Imaging in Patients With Autonomic Failure
Multiple System AtrophyParkinson DiseaseDementia With Lewy Bodies+2 more
Daniel Claassen40 enrolled1 locationNCT04246437
Recruiting
Phase 1
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Parkinson Disease
iRegene Therapeutics Co., Ltd.5 enrolled1 locationNCT07102342
Recruiting
Phase 1Phase 2
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
SafetyPARKINSON DISEASE (Disorder)Apathy
Integrative Research Laboratories AB75 enrolled13 locationsNCT07461220
Recruiting
Phase 1Phase 2
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
Parkinson's Disease
Sumitomo Pharma America, Inc.25 enrolled2 locationsNCT06753331
Not Yet Recruiting
Phase 1
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered BT-409 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of BT-409 in Adults with Parkinson’s disease.
Parkinson's Disease
Diagenta Au PTY LTD12 enrolled1 locationACTRN12626000206325
Not Yet Recruiting
Phase 1
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered BT-409 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of BT-409 in Healthy Volunteers.
Parkinson's Disease
Diagenta AU PTY LTD64 enrolled1 locationACTRN12626000191392